Effect of Paricalcitol Over Vessel Wall

Launched by EFFICE SERVICIOS PARA LA INVESTIGACION S.L. · Feb 20, 2015

Keywords

ClinConnect Summary

Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged between 50 and 75 years.
• • Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).
• • Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.
• • Plasma concentrations of 25 (OH) vitamin D \<30 ng/ml.
• • Without vitamin D supplementation for 3 months before the study.
• • Serum P\> 3.8 mg / dl.
• • Serum Ca\> 9.8 mg / dl.
• • No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).
• • No exclusion criteria for the use of contrast.
• Exclusion Criteria:
• • Allergic reaction to sulfur hexafluoride.
• • Recent unstable cardiac symptoms.
• • Patients with recent coronary intervention (\<7 days)
• • Patients with class III and IV heart failure or severe arrhythmias.
• • Severe pulmonary hypertension.